FLGT Fulgent: תחזית צמיחת רווחים לשנה הבאה

The consensus EPS forecast for the coming year reflects the results of Fulgent Genetics, Inc. (FLGT) pivoting from COVID tests toward oncology diagnostics and subscriptions. The value 20.30 determines the current status of the parameter. Growth is driven by AI platforms that create barriers for partners; however, geopolitics hinder international testing and restrict the supply of essential chemical reagents for laboratories.

As a portfolio manager, I view this indicator as a leading marker of fundamental value that measures the percentage change in expected earnings per share for the coming year. By analyzing the trend of expected net earnings per share, an investor assesses the sensitivity of Fulgent Genetics, Inc. (FLGT) to macroeconomic shocks, which is critical when diversifying the company's revenue through public and private healthcare contracts.